Stay updated on Bladder Cancer Combo Clinical Trial
Sign up to get notified when there's something new on the Bladder Cancer Combo Clinical Trial page.

Latest updates to the Bladder Cancer Combo Clinical Trial page
- Check3 days agoChange DetectedThe record now indicates that results were posted on November 13, 2026, and provides updated cohort-specific treatment descriptions and detailed efficacy and safety outcome measures. The study is listed as terminated for business reasons and is no longer recruiting participants.SummaryDifference11%

- Check10 days agoChange DetectedThe ClinicalTrials.gov record for the pembrolizumab bladder cancer study is displayed, with trial information and outcome measures. The study is marked terminated for business reasons and is no longer recruiting participants.SummaryDifference50%

- Check17 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Bladder Cancer Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bladder Cancer Combo Clinical Trial page.